About Teriparatide
Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for osteoporosis — a compound that stimulates new bone formation rather than merely inhibiting bone resorption. Teriparatide activates the PTH/PTHrP receptor (PTH1R) on osteoblasts; when administered as intermittent pulsatile subcutaneous injections, it drives net bone formation by stimulating osteoblast activity, increasing bone mineral density, improving trabecular microarchitecture, and reducing fracture risk — a distinct mechanism from antiresorptive agents such as bisphosphonates. A comprehensive systematic review and network meta-analysis published in the Annals of Internal Medicine (2023), integrating multiple randomized controlled trials, established teriparatide among the most effective pharmacological interventions for fracture prevention in osteoporosis, with significant reductions in vertebral and non-vertebral fracture risk versus placebo. Teriparatide (Forteo, Eli Lilly) is FDA-approved and requires a prescription; it is indicated for postmenopausal women, men with osteoporosis, and glucocorticoid-induced osteoporosis at high fracture risk, with a maximum treatment duration of two years due to preclinical osteosarcoma findings; biosimilar teriparatide preparations are available in multiple international markets.
Teriparatide Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- November 26, 2002
- Source
- View FDA source →
FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
6 sources cited · 2 strong · 4 moderate
2 Meta-analysis · 4 Cohorts
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.
J Oral Biosci · 2026
# Summary Research found that parathyroid hormone (teriparatide) supplementation consistently improved dental implant integration and peri-implant bone quality in preclinical osteoporotic animal models, with combination treatment approaches showing superior results compared to hormone therapy alone. This study demonstrated that while preclinical evidence supports PTH's potential as an adjunctive strategy to enhance implant outcomes in osteoporotic patients, significant variations in experimental methodologies currently prevent drawing definitive clinical conclusions, necessitating standardized human trials before clinical application.
Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians
Annals of Internal Medicine · 2023
This American College of Physicians network meta-analysis found that teriparatide reduced both clinical and radiographic vertebral fractures in postmenopausal women with osteoporosis and may be more effective than bisphosphonate therapy in very high-risk patients, supporting its established role as an anabolic bone-forming peptide hormone for severe osteoporosis management.
Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross‑sectional study.
BMC Oral Health · 2026
# Summary Research found that while Malaysian medical practitioners demonstrated high awareness of bisphosphonate-related oral complications (96.2%), significant gaps existed in clinical guideline knowledge and preventive practices, with only 58.5% aware of relevant guidelines and fewer than half routinely referring patients for pretreatment dental evaluation. This study demonstrated that despite recognizing medication-related osteonecrosis of the jaw as a serious risk, practitioners showed inconsistent implementation of preventive measures and variable confidence in managing affected patients.
Show 3 more sources ↓
Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adults with osteoporosis: A proportional hazards analysis.
J Orthop · 2026
# Summary This study demonstrated that among osteoporotic adults undergoing lumbosacral fusion, teriparatide showed no significant association with sacral fracture risk in the two-year postoperative period. Researchers observed that vitamin D use was associated with reduced fracture risk, while a history of falls emerged as the strongest predictor of postoperative sacral fracture complications.
Bone Bridge Effect for the Treatment of Acute Osteoporotic Vertebral Compression Fractures: A Multistrategic Approach Using an Anabolic Agent.
Yonsei Med J · 2026
# Summary Research found that patients with osteoporotic vertebral compression fractures treated with anabolic agents—particularly teriparatide combined with denosumab—demonstrated significantly higher rates of bone bridge formation (51.8%), greater increases in bone mineral density, and faster pain relief compared to those receiving anti-resorptive agents alone. This study demonstrated that anabolic agent-based treatment strategies were independent predictors of bone bridge formation and may offer superior outcomes in managing acute osteoporotic vertebral compression fractures.
Consensus on the Treatment of Midshaft Clavicular Fractures in Collegiate Football Players: A Delphi Approach of Sports Medicine Teams.
Orthop J Sports Med · 2026
# Summary Research found that among sports medicine professionals treating midshaft clavicular fractures in collegiate football players, displacement amount, fracture location, player preference, and return-to-play timeline were the most influential factors in treatment decisions, with bone stimulators and specialized padding used more commonly than teriparatide as adjunctive treatments. This Delphi consensus study demonstrated significant variation in treatment approaches across orthopaedic surgeons, sports medicine physicians, and athletic trainers, with limited consensus achieved across the full multidisciplinary panel.
Teriparatide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Teriparatide — Providers & Availability
3 providersClinics
1 providerOnline Vendors
1 providerStay updated on verified Teriparatide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Teriparatide
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for osteoporosis — a compound that stimulates new bone formation rather than merely inhibiting bone resorption. Teriparatide activates the PTH/PTHrP receptor (PTH1R) on osteoblasts; when administered as intermittent pulsatile subcutaneous injections, it drives net bone formation by stimulating osteoblast activity, increasing bone mineral density, improving trabecular microarchitecture, and reducing fracture risk — a distinct mechanism from antiresorptive agents such as bisphosphonates.
bone formation, bone density increase, osteoporosis reversal, fracture risk reduction.
Research on Teriparatide primarily documents effects related to bone formation and bone density increase and osteoporosis reversal and fracture risk reduction. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Teriparatide include osteosarcoma risk (2-year limit), Paget's disease, prior radiation to skeleton. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
3 providers in the directory currently offer Teriparatide.
# Summary Research found that parathyroid hormone (teriparatide) supplementation consistently improved dental implant integration and peri-implant bone quality in preclinical osteoporotic animal models, with combination treatment approaches showing superior results compared to hormone therapy alone. This study demonstrated that while preclinical evidence supports PTH's potential as an adjunctive strategy to enhance implant outcomes in osteoporotic patients, significant variations in experimental methodologies currently prevent drawing definitive clinical conclusions, necessitating standardized human trials before clinical application.